Cardiovascular Business

The cardiovascular business channel offers news and new technologies to aid the business management of the cardiovascular service line.

Black patient being tested for COVID-19 using a nasal swab PCR test. black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to data from the AHA COVID-19 Cardiovascular Disease Registry. #AHA #AHA20 #AHA2020 #COVID19 #SARSCoV2
Feature | Coronavirus (COVID-19)

November 18, 2020 -- A new American Heart Association (AHA) collaborative model for COVID-19 (SARS-CoV-2) research ...

Home November 18, 2020
Home
Feature | Heart Valve Technology

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

Home November 17, 2020
Home
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | Dave Fornell, Editor

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

Home November 17, 2020
Home
Videos | Coronavirus (COVID-19)

Keith Ellis, M.D., is the director of cardiovascular services and the director of the Chest Pain Center at Houston ...

Home November 10, 2020
Home
Two of the top preforming pieces of content in October was the FDA clearance for the first indication for shortened DAPT for Medtronic's Resolute Onyx Drug Eluting Stent. A virtual tour of the new robotic electrophysiology lab at Banner Health led by Pete Weiss, M.D., also was among the most popular cardiology technology content.
Feature

November 2, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home November 02, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
News | FFR Technologies | Dave Fornell, Editor

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from ...

Home October 22, 2020
Home
News | Stents Drug Eluting

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

Home October 16, 2020
Home
News | Coronavirus (COVID-19)

October 14, 2020 — American College of Cardiology (ACC) Quality Summit virtual meeting Oct. 8-9, 2020, featured several ...

Home October 14, 2020
Home
Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.
Feature | Udi Nussinovitch M.D., Ph.D.

This is an overview of some of the biggest cardiology technology advances. These innovations are covered in more detail ...

Home October 09, 2020
Home
Videos | Radial Access

Jordan G. Safirstein, M.D., FACC, FSCAI, director of transradial catheterization for Atlantic Health System’s Morristown ...

Home October 07, 2020
Home
Webinar | Cardiovascular Information Systems (CVIS)

The dynamics of our world are changing rapidly. Cardiologists are being challenged to complete documentation in an ...

Home October 05, 2020
Home
Videos | Artificial Intelligence

Nick West, M.D., chief medical officer for Abbott, explains the details from a survey of 1,400 patients, physicians and ...

Home September 21, 2020
Home
Subscribe Now